Efficacy of Ecabet Sodium for Helicobacter pylori Eradication with Sequential Therapy
10.7704/kjhugr.2018.18.3.180
- Author:
Seol SO
1
;
Ji Yong AHN
;
Hee Kyong NA
;
Kee Wook JUNG
;
Jeong Hoon LEE
;
Do Hoon KIM
;
Kee Don CHOI
;
Ho June SONG
;
Gin Hyug LEE
;
Hwoon Yong JUNG
Author Information
1. Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. ji110@hanmail.net
- Publication Type:Original Article
- Keywords:
Ecabet sodium;
Helicobacter pylori;
Sequential therapy
- MeSH:
Helicobacter pylori;
Helicobacter;
Humans;
Incidence;
Nausea;
Prevalence;
Retrospective Studies;
Sodium;
Vomiting
- From:The Korean Journal of Helicobacter and Upper Gastrointestinal Research
2018;18(3):180-185
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: We aimed to compare the outcomes of Helicobacter pylori eradication in patients receiving sequential therapy (ST) depending on the use of ecabet sodium (ES). MATERIALS AND METHODS: Between January to December 2015, 176 patients randomly received either ST alone (n=72) or 10-day ES therapy combined with ST (n=104). After applying the exclusion criteria, 56 patients were finally assigned to the ST-only group and 84 to the ST with ES group. We retrospectively reviewed and analyzed the H. pylori eradication rate and adverse events between the two groups. RESULTS: Among the 140 patients, 121 (86.4%) achieved successful H. pylori eradication and 24 (17.1%) had adverse events. Eradication was achieved in 50 patients (89.3%) in the ST-only group and in 71 patients (84.5%) in the ST with ES group (P=0.420). No significant difference in the incidence of adverse events was found between the ST-only and ST with ES groups (12.5% vs. 20.2%, respectively; P=0.234). However, the ST with ES group tended to have a higher prevalence of nausea or vomiting than the ST-only group (11.9% vs. 1.8%; P=0.050). CONCLUSIONS: ST showed a good H. pylori eradication rate without deteriorating the adverse events regardless of adding ES.
